Timing of Immunotherapy with Chemotherapy for Advanced Nasopharyngeal Cancer
Treatments studied
Part of Cancer, Ear, nose & throat clinical trials.
This trial is testing the best timing for adding immunotherapy (a treatment that helps your immune system fight cancer) to standard chemotherapy for people with advanced nasopharyngeal cancer that has not spread. It aims to improve treatment effectiveness.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have locally advanced nasopharyngeal cancer (stage II or III), confirmed by biopsy.
- You have at least one tumor that can be measured on scans.
- You are able to perform daily activities with little or no help (ECOG 0-1).
- You have adequate organ function (blood, liver, kidneys, clotting) and are expected to live at least 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment for advanced nasopharyngeal cancer. You will get chemotherapy and radiation, followed by maintenance therapy with an immunotherapy drug called toripalimab to help your immune system fight the cancer.
This trial tests a combination treatment (chemotherapy before, then chemotherapy with radiation) for advanced nasopharyngeal cancer that hasn't spread to distant sites. The goal is to improve survival and control of the disease.
This trial tests a new combination of chemotherapy and immunotherapy drugs for advanced nasopharyngeal cancer that has not spread to distant parts of the body. The goal is to see if this approach works better than standard treatment.
This trial tests whether adding the immunotherapy drug toripalimab to standard chemotherapy (cisplatin and gemcitabine) can help people whose nasopharyngeal cancer has come back or spread. It is for those who haven't yet received other treatments for this advanced stage.
This trial tests adding toripalimab (an immunotherapy) to two different platinum-based chemotherapy regimens as initial treatment for locally advanced nasopharyngeal carcinoma. The goal is to see if this combination is more effective than standard treatment.
This trial studies whether adding toripalimab to radiation plus chemotherapy can improve outcomes for people with advanced nasopharyngeal cancer. It also looks at tumor markers (like PD-L1) using stored tumor tissue or a new biopsy.
Hear when a new Locally Advanced Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.